Apogee Therapeutics Inc
APGE78.640USD
+0.990+1.27%
Market hours （ET）Quotes delayed by 15 min
4.66BMarket Cap
LossP/E TTM
More Details of Apogee Therapeutics Inc Company
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.
Apogee Therapeutics Inc Info
Ticker SymbolAPGE
Company nameApogee Therapeutics Inc
IPO dateJul 14, 2023
CEOHenderson (Michael)
Number of employees196
Security typeOrdinary Share
Fiscal year-endJul 14
Address221 Crescent St.
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02453
Phone16503945230
Websitehttps://apogeetherapeutics.com/
Ticker SymbolAPGE
IPO dateJul 14, 2023
CEOHenderson (Michael)
Company Executives of Apogee Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Carl Dambkowski, M.D.
Mr. Carl Dambkowski, M.D.
Chief Medical Officer
Chief Medical Officer
112.65K
-10900.00%
Mr. Tomas Kiselak
Mr. Tomas Kiselak
Independent Director
Independent Director
51.17K
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Chairman of the Board
Independent Chairman of the Board
20.00K
--
Dr. Michael Henderson, M.D.
Dr. Michael Henderson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Jane Pritchett Henderson
Ms. Jane Pritchett Henderson
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter Harwin
Mr. Peter Harwin
Independent Director
Independent Director
--
--
Ms. Jennifer Fox
Ms. Jennifer Fox
Independent Director
Independent Director
--
--
Dr. Andrew Gottesdiener, M.D.
Dr. Andrew Gottesdiener, M.D.
Independent Director
Independent Director
--
--
Mr. William (Bj) Jones, Jr.
Mr. William (Bj) Jones, Jr.
Independent Director
Independent Director
--
--
Mr. Nimish Shah
Mr. Nimish Shah
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Carl Dambkowski, M.D.
Mr. Carl Dambkowski, M.D.
Chief Medical Officer
Chief Medical Officer
112.65K
-10900.00%
Mr. Tomas Kiselak
Mr. Tomas Kiselak
Independent Director
Independent Director
51.17K
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Chairman of the Board
Independent Chairman of the Board
20.00K
--
Dr. Michael Henderson, M.D.
Dr. Michael Henderson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Jane Pritchett Henderson
Ms. Jane Pritchett Henderson
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter Harwin
Mr. Peter Harwin
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
VR Adviser, LLC
15.49%
Fidelity Management & Research Company LLC
12.55%
Wellington Management Company, LLP
8.61%
RTW Investments L.P.
4.95%
BlackRock Institutional Trust Company, N.A.
4.45%
Other
53.96%
Shareholders
Shareholders
Proportion
VR Adviser, LLC
15.49%
Fidelity Management & Research Company LLC
12.55%
Wellington Management Company, LLP
8.61%
RTW Investments L.P.
4.95%
BlackRock Institutional Trust Company, N.A.
4.45%
Other
53.96%
Shareholder Types
Shareholders
Proportion
Investment Advisor
35.14%
Investment Advisor/Hedge Fund
33.43%
Hedge Fund
20.35%
Venture Capital
17.44%
Corporation
3.99%
Research Firm
3.93%
Private Equity
2.47%
Individual Investor
2.20%
Bank and Trust
0.27%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
398
62.05M
113.16%
-5.68M
2025Q3
401
61.56M
114.17%
+657.36K
2025Q2
380
59.46M
152.78%
-3.62M
2025Q1
350
63.05M
144.49%
-1.71M
2024Q4
317
59.56M
136.18%
+2.59M
2024Q3
286
56.94M
102.46%
+1.98M
2024Q2
257
54.87M
111.46%
+7.98M
2024Q1
220
46.85M
77.95%
+13.42M
2023Q4
148
35.59M
92.12%
+1.64M
2023Q3
108
33.93M
50.63%
+15.10M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
VR Adviser, LLC
8.49M
15.49%
--
--
Sep 30, 2025
Fidelity Management & Research Company LLC
6.88M
12.55%
+243.45K
+3.67%
Sep 30, 2025
Wellington Management Company, LLP
4.72M
8.61%
-161.44K
-3.30%
Sep 30, 2025
RTW Investments L.P.
2.71M
4.95%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.44M
4.45%
+134.04K
+5.82%
Sep 30, 2025
The Vanguard Group, Inc.
2.24M
4.09%
+136.69K
+6.50%
Sep 30, 2025
Access Industries, Inc.
2.19M
3.99%
+250.00K
+12.88%
Sep 30, 2024
Driehaus Capital Management, LLC
2.16M
3.94%
-152.25K
-6.59%
Sep 30, 2025
Fairmount Funds Management LLC
2.05M
3.74%
--
--
Oct 10, 2025
State Street Investment Management (US)
1.66M
3.02%
+396.29K
+31.47%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Goldman Sachs Future Health Care Equity ETF
1.11%
ALPS Medical Breakthroughs ETF
1.1%
JPMorgan Healthcare Leaders ETF
1.05%
Virtus LifeSci Biotech Clinical Trials ETF
0.92%
State Street SPDR S&P Biotech ETF
0.91%
First Trust Multi-Manager Small Cap Opportunities ETF
0.81%
Direxion Daily S&P Biotech Bull 3X Shares
0.56%
JPMorgan Fundamental Data Science Small Core ETF
0.44%
ProShares Ultra Nasdaq Biotechnology
0.4%
Invesco Nasdaq Biotechnology ETF
0.25%
View more
Goldman Sachs Future Health Care Equity ETF
Proportion1.11%
ALPS Medical Breakthroughs ETF
Proportion1.1%
JPMorgan Healthcare Leaders ETF
Proportion1.05%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.92%
State Street SPDR S&P Biotech ETF
Proportion0.91%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.81%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.56%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.44%
ProShares Ultra Nasdaq Biotechnology
Proportion0.4%
Invesco Nasdaq Biotechnology ETF
Proportion0.25%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Apogee Therapeutics Inc?
The top five shareholders of Apogee Therapeutics Inc are:
VR Adviser, LLC holds 8.49M shares, accounting for 15.49% of the total shares.
Fidelity Management & Research Company LLC holds 6.88M shares, accounting for 12.55% of the total shares.
Wellington Management Company, LLP holds 4.72M shares, accounting for 8.61% of the total shares.
RTW Investments L.P. holds 2.71M shares, accounting for 4.95% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.44M shares, accounting for 4.45% of the total shares.
VR Adviser, LLC holds 8.49M shares, accounting for 15.49% of the total shares.
Fidelity Management & Research Company LLC holds 6.88M shares, accounting for 12.55% of the total shares.
Wellington Management Company, LLP holds 4.72M shares, accounting for 8.61% of the total shares.
RTW Investments L.P. holds 2.71M shares, accounting for 4.95% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.44M shares, accounting for 4.45% of the total shares.
What are the top three shareholder types of Apogee Therapeutics Inc?
The top three shareholder types of Apogee Therapeutics Inc are:
VR Adviser, LLC
Fidelity Management & Research Company LLC
Wellington Management Company, LLP
VR Adviser, LLC
Fidelity Management & Research Company LLC
Wellington Management Company, LLP
How many institutions hold shares of Apogee Therapeutics Inc (APGE)?
As of 2025Q4, 398 institutions hold shares of Apogee Therapeutics Inc, with a combined market value of approximately 62.05M, accounting for 113.16% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.00%.
What is the biggest source of revenue for Apogee Therapeutics Inc?
In --, the -- business generated the highest revenue for Apogee Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
